Intravenous Sodium Fluorescein Versus Oral Phenazopyridine for Ureteral Patency

• Status: Unknown status
• Trial end date: 2019-12-01
• Target enrollment: 0
• Participant gender: Female

Summary

To determine the safety profile of sodium fluorescein in women undergoing cystoscopy during gynecologic surgery. To determine if either oral phenazopyridine or sodium fluorescein result in shorter cystoscopy times.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospitals Cleveland Medical Center
• Collaborators: Alex Soriano; Graham Chapman; Megan Billow; Sangeeta Mahajan; Sherif El-Nashar

Criteria

Inclusion Criteria:

• - Patients must be 18 years or older as well as willing and able to provide informed consent

• Patients undergoing a scheduled gynecologic procedure with cystoscopy

Exclusion Criteria:

• - Patients are younger than 18 years

• Patients are unable or unwilling to provide informed consent

• Patients with a history of an allergic reaction to sodium fluorescein or phenazopyridine

• Patients with a history of renal insufficiency

• Patients with a history of liver disease

• Patients with a history of sickle cell disease

• Patients with a history of glucose-6-phosphate dehydrogenase deficiency

• Patients with a history of chronic obstructive pulmonary disease or currently being treated for asthma